(Q44623048)

4 December 2017

title

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study (English)

1 reference

4 December 2017

1 reference

Eduardo F Mysler

1

1 reference

4 December 2017

Alberto J Spindler

2

1 reference

4 December 2017

Renato Guzman

3

1 reference

4 December 2017

Marc Bijl

4

1 reference

4 December 2017

David Jayne

5

1 reference

4 December 2017

Richard A Furie

6

1 reference

4 December 2017

Frédéric A Houssiau

7

1 reference

4 December 2017

Jorn Drappa

8

1 reference

4 December 2017

David Close

9

1 reference

4 December 2017

Romeo Maciuca

10

1 reference

4 December 2017

Kajal Rao

11

1 reference

4 December 2017

Saba Shahdad

12

1 reference

4 December 2017

Paul Brunetta

13

1 reference

4 December 2017

publication date

1 September 2013

1 reference

4 December 2017

published in

Arthritis & Rheumatology

1 reference

4 December 2017

volume

65

1 reference

4 December 2017

issue

9

1 reference

4 December 2017

page(s)

2368-2379

1 reference

Lupus nephritis: current update

4 December 2017

cites work

1 reference

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

Current treatment of lupus nephritis

21 January 2018

1 reference

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis

21 January 2018

1 reference

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

21 January 2018

1 reference

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

21 January 2018

1 reference

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

21 January 2018

1 reference

Anti-DNA and autoantibodies

21 January 2018

1 reference

Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study

21 January 2018

1 reference

In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis

21 January 2018

1 reference

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

21 January 2018

1 reference

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts

21 January 2018

1 reference

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

21 January 2018

1 reference

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression

21 January 2018

1 reference

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.38037

1 reference

4 December 2017

1 reference